


PHARMACEUTICAL 2019

CHIMERIX INC Rank 50 of 363









PHARMACEUTICAL 2019





The relative strengths and weaknesses of CHIMERIX INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHIMERIX INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of CHIMERIX INC is the variable Research and Development, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 232%, being 195% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	189,458
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,966
Liabilities, Non-Current	144
Other Assets	46
Other Compr. Net Income	871
Other Expenses	348
Other Liabilities	0
Other Net Income	2,479
Other Revenues	7,216
Property and Equipment	1,210
Research and Development	55,239
Selling, General and Administrative Expense	23,582

Output Variable	Value in 1000 USD
Assets	190,714
Liabilities	13,110
Expenses	79,169
Revenues	7,216
Stockholders Equity	177,604
Net Income	-69,474
Comprehensive Net Income	-69,038
Economic Capital Ratio	232%

